Detection of alternative splicing during epithelial-mesenchymal transition

Journal of Visualized Experiments

Volumn , Issue 92, 2014, Pages

  Huang, Huilin ^a   Xu, Yilin ^a   Cheng, Chonghui ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alternative splicing; Cellular Biology; EMT; Issue 92; Primer design; Real time PCR; RNA; Splice isoforms

Indexed keywords

CADHERIN; CD44 PROTEIN, HUMAN; FIBRONECTIN; HERMES ANTIGEN; ISOPROTEIN; MESSENGER RNA; OCCLUDIN; OCLN PROTEIN, HUMAN; VIMENTIN;

ALTERNATIVE RNA SPLICING; BIOSYNTHESIS; CYTOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENETICS; HUMAN; MAMMARY GLAND; METABOLISM; PHYSIOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALTERNATIVE SPLICING; ANTIGENS, CD44; CADHERINS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; HUMANS; MAMMARY GLANDS, HUMAN; OCCLUDIN; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VIMENTIN;

EID: 84908339439     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51845     Document Type: Article

References (43)

1. Thiery, J. P., & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7, 131-142, doi:10.1038/nrm1835, (2006).
2. Yang, J., & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 14, 818-829, doi:10.1016/j.devcel.2008.05.009, (2008).
3. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117, 927-939, doi:10.1016/j.cell.2004.06.006, (2004).
4. Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2, 84-89, doi:10.1038/35000034, (2000).
5. Cano, A. et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2, 76-83, doi:10.1038/35000025, (2000).
6. Comijn, J. et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 7, 1267-1278, doi:S1097-2765(01)00260-X, (2001).
7. Bolos, V. et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 116, 499-511, doi:10.1242/jcs.00224, (2003).
8. Eger, A. et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 24, 2375-2385, doi:10.1038/sj.onc.1208429, (2005).
9. Shapiro, I. M. et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 7, e1002218, doi:10.1371/journal.pgen.1002218, (2011).
10. Warzecha, C. C. et al. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 29, 3286-3300, doi:10.1038/emboj.2010.195, (2010).
11. Brown, R. L. et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 121, 1064-1074, doi:10.1172/JCI44540, (2011).
12. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 456, 470-476, doi:10.1038/nature07509, (2008).
13. Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 40, 1413-1415, doi:10.1038/ng.259, (2008).
14. Liu, S., & Cheng, C. Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA. 4, 547-566, doi:10.1002/wrna.1178, (2013).
15. Shtivelman, E., Lifshitz, B., Gale, R. P., Roe, B. A., & Canaani, E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 47, 277-284, doi:0092-8674(86)90450-2, (1986).
16. Krangel, M. S. Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med. 163, 1173-1190, doi:10.1084/jem.163.5.1173, (1986).
17. Brickell, P. M., Latchman, D. S., Murphy, D., Willison, K., & Rigby, P. W. Activation of a Qa/Tla class I major histocompatibility antigen gene is a general feature of oncogenesis in the mouse. Nature. 306, 756-760, doi:10.1038/306756a0, (1983).
18. Barbaux, S. et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet. 17, 467-470, doi:10.1038/ng1297-467, (1997).
19. Charlet, B. N. et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell. 10, 45-53, doi:S1097276502005725, (2002).
20. Hutton, M. et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393, 702-705, doi:10.1038/31508, (1998).
21. Kohsaka, T. et al. Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome. Hum Mutat. 14, 466-470, doi:10.1002/(SICI)1098-1004(199912), (1999).
22. Philips, A. V., Timchenko, L. T., & Cooper, T. A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 280, 737-741, doi: 10.1126/science.280.5364.737, (1998).
23. Savkur, R. S., Philips, A. V., & Cooper, T. A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 29, 40-47, doi:10.1038/ng704, (2001).
24. Spillantini, M. G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 95, 7737-7741, (1998).
25. Wang, J. et al. Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. Hum Mol Genet. 4, 599-606, doi:10.1093/hmg/4.4.599, (1995).
26. Graubert, T. A. et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 44, 53-57, doi:10.1038/ng.1031, (2012).
27. Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 365, 1384-1395, doi:10.1056/NEJMoa1103283, (2011).
28. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 478, 64-69, doi:10.1038/nature10496, (2011).
29. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133, 704-715, doi:10.1016/j.cell.2008.03.027, (2008).
30. Reinke, L. M., Xu, Y., & Cheng, C. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J Biol Chem. 287, 36435-36442, doi:10.1074/jbc.M112.397125, (2012).
31. Serini, G., & Gabbiani, G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res. 250, 273-283, doi:10.1006/excr.1999.4543, (1999).
32. Zavadil, J., & Bottinger, E. P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 24, 5764-5774, doi:10.1038/sj.onc.1208927, (2005).
33. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45, doi:10.1093/nar/29.9.e45, (2001).
34. Hellemans, J., Mortier, G., De Paepe, A., Speleman, F., & Vandesompele, J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 8, R19, doi:10.1186/gb-2007-8-2-r19, (2007).
35. Boutz, P. L. et al. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev. 21, 1636-1652, doi:10.1101/gad.1558107, (2007).
36. Salomonis, N. et al. Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci U S A. 107, 10514-10519, doi:10.1073/pnas.0912260107, (2010).
37. Calarco, J. A. et al. Regulation of vertebrate nervous system alternative splicing and development by an SR-related protein. Cell. 138, 898-910, doi:10.1016/j.cell.2009.06.012, (2009).
38. Grabowski, P. Alternative splicing takes shape during neuronal development. Curr Opin Genet Dev. 21, 388-394, doi:10.1016/j.gde.2011.03.005, (2011).
39. Seol, D. W., & Billiar, T. R. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem. 274, 2072-2076, (1999).
40. Srinivasula, S. M. et al. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Res. 59, 999-1002, (1999).
41. Akgul, C., Moulding, D. A., & Edwards, S. W. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci. 61, 2189-2199, doi:10.1007/s00018-004-4001-7, (2004).
42. Cooper, T. A. Use of minigene systems to dissect alternative splicing elements. Methods. 37, 331-340, doi:10.1016/j.ymeth.2005.07.015, (2005).
43. Cheng, C., & Sharp, P. A. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol. 26, 362-370, doi:10.1128/MCB.26.1.362-370.2006, (2006).